Pliant Therapeutics (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.
Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.
The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.
The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.
Price: 1.65, Change: +0.02, Percent Change: +1.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.